摘要
过氧化物酶体增殖物激活受体 (PPARs)是核受体超家族成员之一。PPARα、PPARγ可分别被氯贝特类和TZD类药物特异性激活 ,调节脂代谢、改善胰岛素抵抗 ;有研究表明PPARβ也参与脂肪代谢。因此 ,以PPARs为药物靶标 ,发现和优化单一或双重激动剂将为肥胖和
The peroxisome prolifrator-activated receptors(PPARs)α and γ constitute a subfamily of nuclear receptors. PPARα has been shown to be activat ed by the hypolipidemic drugs of the fibrate class; While the antidiabetic TZD a re synthetic ligands for PPARγ. Upon binding and activation by their ligands, t hey regulate the transcription of numerous genes involving lipid metabolism and insulin resistance. The research indicated that PPARβ also plays a key role in lipid metabolism. PPARs therefore constitute interesting targets for the develop ment of single and dual agonists useful in the treatment of obesity and type 2 d iabetes.
出处
《中国药理学通报》
CAS
CSCD
北大核心
2004年第3期241-244,共4页
Chinese Pharmacological Bulletin
